secwatch.observer — SEC 8-K summary
======================================

Issuer:     Metagenomi Therapeutics, Inc. (MGX)
CIK:        0001785279
Form:       8-K
Filed at:   2024-09-03T23:59:59+00:00
Accession:  0000950170-24-102805
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Metagenomi reports 12-month durable FVIII activity in preclinical hemophilia A study
--------------------------------------------------------------------------------

- All three NHPs showed durable FVIII activity at 12 months: 82%, 41%, and 9%.
- FVIII levels consistent from 3-6 month to 9-12 month time points; no significant decline.
- Liver biopsy showed gene integration in forward orientation at 0.7% to 2.9%.
- Treatment well tolerated with only moderate transient liver transaminase elevations.
- Program on track for IND filing in 2026; company declared MGX-001 as development candidate.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1785279/000095017024102805/0000950170-24-102805-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1785279/000095017024102805/mgx-20240903.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-102805

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer